By the end of 2017, CTS has secured three source plasma partners and continues to seek additional partners in the plasma industry in order to continue to diversify CTS’s revenue stream.
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.
In October, due to demand from existing healthcare partners, CTS began testing blood donors for anti...
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).